Mga Batayang Estadistika
| LEI | 529900EV44GVDN1DCX77 |
| CIK | 1515673 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ultragenyx Pharmaceutical Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| August 5, 2025 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update Second quarter total revenue of $166 million, Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 mill |
|
| August 5, 2025 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2025 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Com |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) ULTRAGENYX PHARMACEUTICAL INC. |
|
| July 18, 2025 |
Third Amendment to Employment Inducement Plan Exhibit 4.8 THIRD AMENDMENT TO THE Ultragenyx Pharmaceutical Inc. Employment Inducement Plan WHEREAS, Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Company”) maintains the Ultragenyx Pharmaceutical Inc. Employment Inducement Plan, as amended (the “Plan”); and WHEREAS, pursuant to Section 9 of the Plan, the Compensation Committee may amend the Plan at any time and for any purpose as |
|
| July 18, 2025 |
Second Amended and Restated 2023 Incentive Plan Exhibit 4.4 Ultragenyx Pharmaceutical Inc. Second Amended and Restated 2023 Incentive Plan 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. 2. PURPOSE The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock-based and ot |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 09, 2025 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 19, 2025 |
Second Amended and Restated 2023 Incentive Plan Exhibit 10.1 Ultragenyx Pharmaceutical Inc. Second Amended and Restated 2023 Incentive Plan 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. 2. PURPOSE The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock-based and o |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| May 7, 2025 |
Form of Performance Stock Unit Agreement (2025) Exhibit 10.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS A PRIVATE OR CONFIDENTIAL. Name: [●] Target Number of Performance Stock Units subject to Award: [●] Date of Grant: [●] ULTRAGENYX PHARMACEUTICAL INC. 2023 INCENTIVE PLAN PERFORMANCE STOCK UNIT |
|
| May 6, 2025 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 mill |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2025 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy |
|
| March 28, 2025 |
ULTRAGENYX PHARMACEUTICAL INC. - DEF A14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permi |
|
| February 19, 2025 |
Exhibit 10.77 Addendum #7 To The Lease Dated on or about July 1, 2011 By and Between Condiotti Enterprises, Inc. ("Lessor") And Ultragenyx Pharmaceutical Inc. ("Lessee") On or about July 1, 2011 Lessor and Lessee entered into a lease and Addendum 1 for approximately 19,916 square feet, comprising the entire second floor of the Premises located at 60 Leveroni Court, Novato, California. Subsequent t |
|
| February 19, 2025 |
Subsidiaries of Ultragenyx Pharmaceutical Inc. Exhibit 21.1 Significant Subsidiaries of Ultragenyx Pharmaceutical Inc. Name of Subsidiary Jurisdiction of Incorporation Ultragenyx Holdco LLC Delaware Rare Delaware Inc. Delaware Amlogenyx Inc. Delaware Ultragenyx UK Ltd United Kingdom Ultragenyx Europe GmbH Switzerland Ultragenyx Germany GmbH Germany Ultragenyx Brasil Farmacêutica Ltda Brazil Ultragenyx Argentina SRL Argentina Ultragenyx Netherl |
|
| February 19, 2025 |
Exhibit 10.89 FOURTH AMENDMENT TO LEASE THIS FOURTH AMENDMENT TO LEASE (this “Fourth Amendment”) is made as of December 13, 2024 (the “Fourth Amendment Effective Date”), by and between GI ETS SHORELINE LLC, a Delaware limited liability company (“Landlord”), and ULTRAGENYX PHARMACEUTICAL INC., a Delaware corporation (“Tenant”). WHEREAS, Landlord (as successor-in-interest to ARE-San Francisco No. 17 |
|
| February 19, 2025 |
Exhibit 10.93 FIRST AMENDMENT TO LEASE This First Amendment to Lease (this “Amendment”) is made and entered into as of March 12, 2024, by and BRICKBOTTOM I QOZB LP, a Delaware limited partnership transacting business in Massachusetts as BRICKBOTTOM I QOZB LIMITED PARTNERSHIP (“Landlord”), and ULTRAGENYX PHARMACEUTICAL INC., a Delaware corporation (“Tenant”). W I T N E S S E T H: WHEREAS, Landlord |
|
| February 19, 2025 |
Form of Performance Stock Unit Agreement (2024) Exhibit 10.38 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS A PRIVATE OR CONFIDENTIAL. Name: [●] Target Number of Performance Stock Units subject to Award: [●] Date of Grant: [●] ULTRAGENYX PHARMACEUTICAL INC. 2023 INCENTIVE PLAN PERFORMANCE STOCK UNI |
|
| February 19, 2025 |
Ultragenyx Insider Trading Policy Exhibit 19.1 Ultragenyx Pharmaceutical Inc. INSIDER TRADING POLICY Approved: March 15, 2023 This Insider Trading Policy (this “Policy”) applies to all employees, officers, directors and consultants of Ultragenyx Pharmaceutical Inc. and its subsidiaries (collectively, the “Company”) as well as your family members, household members and entities controlled by you (as described below). This Policy is |
|
| February 19, 2025 |
Exhibit 10.15 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS A PRIVATE OR CONFIDENTIAL. November 18, 2020 KYOWA KIRIN INC. (1) AND ULTRAGENYX PHARMACEUTICAL INC. (2) SUPPLY AGREEMENT CONTENTS Clause Heading Page 1 DEFINITIONS 3 2 DURATION 10 3 APPOINTM |
|
| February 19, 2025 |
Exhibit 10.16 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS A PRIVATE OR CONFIDENTIAL. AMENDMENT NO.1 TO SUPPLY AGREEMENT This Amendment No.1 to the Supply Agreement (“Amendment No.1”), effective as of September 13, 2024 (“Effective Date”), is made an |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36276 Ultragenyx Pharmaceutical Inc |
|
| February 19, 2025 |
Exhibit 10.84 FIFTH AMENDMENT TO LEASE AGREEMENT THIS FIFTH AMENDMENT TO LEASE AGREEMENT (this “Fifth Amendment”) is made as of this 25th day of November, 2024, between ARE-MA REGION NO. 20, LLC, a Delaware limited liability company (“Landlord”), and ULTRAGENYX PHARMACEUTICAL INC., a Delaware corporation (“Tenant”). RECITALS: A. Tenant and Landlord are parties to that certain Lease Agreement dated |
|
| February 13, 2025 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update 2024 Total Revenue of $560 million, exceeding guidance Crysvita® revenue of $410 million and Dojolvi® revenue of $88 million 2025 Financial Guidance: Total Revenue between $640 million to $670 million, Crysvita reve |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (C |
|
| February 12, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) EX-1 2 jointfilingstatement.htm EXHIBIT 1 EXHIBIT 1 to SCHEDULE 13G JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity |
|
| February 10, 2025 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Ultragenyx Pharmaceutical Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of |
|
| January 13, 2025 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Media Carolyn Wang [email protected] Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, |
|
| January 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Co |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (C |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (C |
|
| November 14, 2024 |
SC 13G/A 1 p24-3270sc13ga.htm ULTRAGENYX PHARMACEUTICAL INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ultragenyx Pharmaceutical Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 90400D108 (CUSIP Number) September 30, 2024 (Date of event which requires filing of t |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (C |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| November 5, 2024 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of $98 million and Dojolvi® revenue of $21 million Reaffirmed 2024 expected total revenue guidance of $530 million to $550 mi |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 05, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (C |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 07, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Co |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 03, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Co |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| August 1, 2024 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update Second quarter total revenue of $147 million, Crysvita® revenue of $114 million and Dojolvi® revenue of $19 million Increased 2024 expected total revenue guidance to $530 million to $550 million NOVATO, Calif. – August 01, 2024 – |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Com |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 12, 2024 |
Amended and Restated 2023 Incentive Plan Exhibit 4.4 Ultragenyx Pharmaceutical Inc. Amended and Restated 2023 Incentive Plan 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. 2. PURPOSE The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock-based and other inc |
|
| July 12, 2024 |
As filed with the Securities and Exchange Commission on July 12, 2024 As filed with the Securities and Exchange Commission on July 12, 2024 Registration No. |
|
| July 12, 2024 |
Second Amendment to Employment Inducement Plan Exhibit 4.7 SECOND AMENDMENT TO THE Ultragenyx Pharmaceutical Inc. Employment Inducement Plan WHEREAS, Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Company”) maintains the Ultragenyx Pharmaceutical Inc. Employment Inducement Plan, as amended (the “Plan”); and WHEREAS, pursuant to Section 9 of the Plan, the Compensation Committee may amend the Plan at any time and for any purpose as |
|
| July 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) ULTRAGENYX PHARMACEUTICAL INC. |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 21, 2024 |
Amended and Restated 2023 Incentive Plan Exhibit 10.1 Ultragenyx Pharmaceutical Inc. Amended and Restated 2023 Incentive Plan 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. 2. PURPOSE The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock-based and other in |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 ULTRAGENYX PHARMACEUTICAL INC. |
|
| June 17, 2024 |
Exhibit 4.1 ULTRAGENYX PHARMACEUTICAL INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: June [ ], 2024 Ultragenyx Pharmaceutical, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its |
|
| June 17, 2024 |
Exhibit 1.1 ULTRAGENYX PHARMACEUTICAL INC. 7,435,898 Shares of Common Stock and pre-funded warrants to purchase 1,538,501 Shares of Common Stock Underwriting Agreement June 13, 2024 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 BofA Securities, Inc. One Bryant Park New York, New York 10036 TD Securities |
|
| June 14, 2024 |
Joint Book-Running Managers J.P. Morgan Goldman Sachs & Co. LLC BofA Securities TD Cowen Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277226 Prospectus Supplement (To Prospectus dated February 21, 2024) 7,435,898 shares Pre-funded warrants to purchase 1,538,501 shares Common Stock We are offering 7,435,898 of shares of our common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,538,501 shares of our common stock. The |
|
| June 14, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM 424(b)(5) (Form Type) ULTRAGENYX PHARMACEUTICAL INC. |
|
| June 12, 2024 |
Joint Book-Running Managers J.P. Morgan Goldman Sachs & Co. LLC BofA Securities TD Cowen Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277226 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permit |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 17, 2024 |
Going beyond every day.™ 60 Leveroni Court Novato, California 94949 May 17, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attn: Tracie Mariner; Kevin Vaughn RE: Ultragenyx Pharmaceutical Inc. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 1-36276 Dear Tracie Mariner and Kevin Vaughn: We ar |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 02, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 2, 2024 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of $375 milli |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy |
|
| April 26, 2024 |
Notice of Annual Meeting of Stockholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 21, 2024 |
Form of Non-Statutory Stock Option Agreement (Annual Grant for Directors) (2023 Plan) Exhibit 10.33 Name: Number of Shares of Stock subject to Stock Option: Price Per Share: Date of Grant: Vesting Start Date: Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan Non-statutory Stock Option Agreement (Directors) This agreement (this “Agreement”) evidences a stock option granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Optionee”) pursuant to and subject |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36276 Ultragenyx Pharmaceutical Inc |
|
| February 21, 2024 |
As filed with the Securities and Exchange Commission on February 21, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 21, 2024 Registration No. |
|
| February 21, 2024 |
Sales Agreement, by and between the Company and Cowen and Company, LLC, dated February 21, 2024. Exhibit 1.2 ULTRAGENYX PHARMACEUTICAL INC. $350,000,000 SALES AGREEMENT February 21, 2024 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, fro |
|
| February 21, 2024 |
Form of Restricted Stock Unit Agreement (Employees) (2023 Plan) Exhibit 10.32 Name: Number of Restricted Stock Units subject to Award: Date of Grant: ULTRAGENYX PHARMACEUTICAL INC. 2023 INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT (EMPLOYEES) This agreement (this “Agreement”) evidences an award (the “Award”) of restricted stock units (the “Restricted Stock Units”) granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Grantee”) pu |
|
| February 21, 2024 |
Subsidiaries of Ultragenyx Pharmaceutical Inc. Exhibit 21.1 Significant Subsidiaries of Ultragenyx Pharmaceutical Inc. Name of Subsidiary Jurisdiction of Incorporation Ultragenyx Holdco LLC Delaware Rare Delaware Inc. Delaware GeneTx Biotherapeutics LLC Delaware Ultragenyx UK Ltd United Kingdom Amlogenyx Inc. Delaware Ultragenyx Europe GmbH Switzerland Ultragenyx Germany GmbH Germany Ultragenyx Brasil Farmacêutica Ltda Brazil Ultragenyx Argent |
|
| February 21, 2024 |
Form of Non-Statutory Stock Option Agreement (Grant for New Directors) (2023 Plan) Exhibit 10.35 Name: Number of Shares of Stock subject to Stock Option: Price Per Share: Date of Grant: Vesting Start Date: Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan Non-statutory Stock Option Agreement (Directors) This agreement (this “Agreement”) evidences a stock option granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Optionee”) pursuant to and subject |
|
| February 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ULTRAGENYX PHARMACEUTICAL INC. |
|
| February 21, 2024 |
Ultragenyx Pharmaceutical Inc. Clawback Policy Exhibit 97.1 ULTRAGENYX PHARMACEUTICAL INC. CLAWBACK POLICY This Clawback Policy (this “Policy”) has been adopted by the Board of Directors (the “Board”) of Ultragenyx Pharmaceutical Inc. (the “Company”) effective October 2, 2023 (the “Effective Date”) and replaces the Company’s Clawback Policy dated December 13, 2017 in its entirety. This Policy is administered by the Compensation Committee (the |
|
| February 21, 2024 |
Form of Non Statutory Stock Option Agreement (Employees)(2023 Plan) Exhibit 10.31 Name: Number of Shares of Stock subject to Stock Option: Price Per Share: Date of Grant: Vesting Start Date: Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan Non-statutory Stock Option Agreement (Employees) This agreement (this “Agreement”) evidences a stock option granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Optionee”) pursuant to and subject |
|
| February 21, 2024 |
Form of Restricted Stock Unit Agreement (Annual Grant for Directors) (2023 Plan) Exhibit 10.34 Name: Number of Restricted Stock Units subject to Award: Date of Grant: Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan Restricted Stock Unit Agreement (Directors) This agreement (this “Agreement”) evidences an award (the “Award”) of restricted stock units (the “Restricted Stock Units”) granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Grantee”) pu |
|
| February 21, 2024 |
Form of Restricted Stock Unit Agreement (Grant for New Directors) (2023 Plan) Exhibit 10.36 Name: Number of Restricted Stock Units subject to Award: Date of Grant: Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan Restricted Stock Unit Agreement (Directors) This agreement (this “Agreement”) evidences an award (the “Award”) of restricted stock units (the “Restricted Stock Units”) granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Grantee”) pu |
|
| February 21, 2024 |
Exhibit 10.18 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS A PRIVATE OR CONFIDENTIAL. Commercial Supply Agreement Triheptanoin Ultrapure Between Ultragenyx Pharmaceutical Inc. 60 Leveroni Court Novato, CA 94949 USA (Herein known as UGX) And IOI Oleo |
|
| February 21, 2024 |
Exhibit 4.2 ULTRAGENYX PHARMACEUTICAL INC. Debt Securities Indenture Dated as of , 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c |
|
| February 21, 2024 |
Form of Incentive Stock Option Agreement (2023 Plan) Exhibit 10.30 Name: Number of Shares of Stock subject to Stock Option: Price Per Share: Date of Grant: Vesting Start Date: Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan incentive Stock Option Agreement This agreement (this “Agreement”) evidences a stock option granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Optionee”) pursuant to and subject to the terms of |
|
| February 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (C |
|
| February 15, 2024 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update 2023 Total Revenue of $434 million, Crysvita® revenue of $328 million and Dojolvi® revenue of $71 million 2024 Financial Guidance: Total Revenue between $500 million and $530 million, Crysvita revenue of $375 millio |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ultragenyx Pharmaceutical Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 90400D108 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| February 13, 2024 |
RARE / Ultragenyx Pharmaceutical Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Ultragenyx Pharmaceutical Inc Title of Class of Securities: Common Stock CUSIP Number: 90400D108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 13, 2024 |
RARE / Ultragenyx Pharmaceutical Inc. / SANDS CAPITAL MANAGEMENT, LLC Passive Investment SC 13G 1 rare13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO Section 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO Section 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. ) * Ultragenyx Pharmaceutical Inc. (Name of Issuer) Common Stock, par v |
|
| February 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Ultragenyx Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90400D108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| January 8, 2024 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Media Carolyn Wang [email protected] Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue of $70 m |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 07, 2024 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Co |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (C |
|
| December 21, 2023 |
Second Amended and Restated Bylaws Exhibit 3.1 ULTRAGENYX PHARMACEUTICAL INC. (the “Corporation”) SECOND AMENDED & RESTATED BYLAWS SECTION 1 - STOCKHOLDERS Section 1.1. Annual Meeting. An annual meeting of the stockholders for the election of directors to succeed those whose term expire and for the transaction of such other business as may properly come before the meeting shall be held at the place, if any, within or without the St |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (C |
|
| November 2, 2023 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Media Jeff Blake [email protected] Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update Third quarter 2023 total revenue of $98.1 million, Crysvita® revenue of $74.9 million and Dojolvi® revenue of $16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 ULTRAGENYX PHARMACEUTICAL INC. |
|
| October 23, 2023 |
Exhibit 1.1 ULTRAGENYX PHARMACEUTICAL INC. 8,333,334 Shares of Common Stock and pre-funded warrants to purchase 1,666,722 Shares of Common Stock Underwriting Agreement October 18, 2023 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 BofA Securities, Inc. One Bryant Park New York, New York 10036 Cowen and C |
|
| October 23, 2023 |
Exhibit 4.1 ULTRAGENYX PHARMACEUTICAL INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: October [ ], 2023 Ultragenyx Pharmaceutical, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or |
|
| October 20, 2023 |
Joint Book-Running Managers J.P. Morgan Goldman Sachs & Co. LLC BofA Securities TD Cowen Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-253008 Prospectus Supplement (To Prospectus dated February 12, 2021) 8,333,334 shares Pre-funded warrants to purchase 1,666,722 shares Common Stock We are offering 8,333,334 shares of our common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,666,722 shares of our common stock. The pu |
|
| October 20, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM 424(b)(5) (Form Type) ULTRAGENYX PHARMACEUTICAL INC. |
|
| October 19, 2023 |
Issuer Free Writing Prospectus Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated October 18, 2023 Relating to Preliminary Prospectus Supplement Dated October 17, 2023 Registration Statement No. |
|
| October 17, 2023 |
Joint Book-Running Managers J.P. Morgan Goldman Sachs & Co. LLC BofA Securities TD Cowen Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-253008 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permit |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Co |
|
| October 16, 2023 |
GTX-102 for Angelman Syndrome Phase 1/2 Clinical Study Update © 2023 Ultragenyx Pharmaceutical Inc. |
|
| October 16, 2023 |
Exhibit 99.1 Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bon |
|
| October 16, 2023 |
EX-99.2 Exhibit 99.2 Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease Treatment with setrusumab (UX143) for at least 6 months resulted in 67% reduction in annualized fracture rate in patients with OI in Phase 2/3 Orbit study Quantitative data from the Phase 1/2 stu |
|
| September 11, 2023 |
RARE / Ultragenyx Pharmaceutical Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Ultragenyx Pharmaceutical Inc. Title of Class of Securities: Common Stock CUSIP Number: 90400D108 Date of Event Which Requires Filing of this Statement: August 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 06, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) ( |
|
| September 8, 2023 |
Exhibit 10.1 Going beyond every day.™ September 6, 2023 Howard Horn Re: Amendment No. 1 to Offer Letter Dear Howard: On behalf of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”), I am pleased to present to you this Amendment No. 1 (this “Amendment”), which amends the Offer of Employment Letter Agreement with you dated June 22, 2023 (the “Offer Letter”) as follows: 1. The first intro |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| August 4, 2023 |
Exhibit 10.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS A PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 13 TO COLLABORATION AND LICENSE AGREEMENT This Amendment No. 13 to the Collaboration and License Agreement (“Amendment”) is made and entered into by an |
|
| August 3, 2023 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Media Jeff Blake [email protected] Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update Second quarter 2023 total revenue of $108.3 million, Crysvita® revenue of $83.0 million and Dojolvi® revenue of $16.5 million Total revenue grew 21% and total Crysvita revenue grew 20% versus |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Com |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 12, 2023 |
Exhibit 99.1 Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy NOVATO, Calif. — July 12, 2023 — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today announced that it has appointed Howard Horn as executive vice pr |
|
| July 12, 2023 |
Offer Letter, dated June 2, 2023, between Ultragenyx Pharmaceutical Inc. and Howard Horn Exhibit 10.1 Going beyond every day.™ June 22, 2023 Howard Horn Dear Howard: Re: Offer of Employment On behalf of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”), I am pleased to offer you the position of Chief Financial Officer and Executive Vice President, Corporate Strategy (“CFO and EVP, Corporate Strategy”), on the following terms, commencing on or around October 16, 2023 (the |
|
| July 6, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 06, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 6, 2023 |
Exhibit 99.1 Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) Pivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatric and young adult patients Newly initiated Phase 3 Cosmic study now enrolling approximately 65 younger pediatric patients NOVATO, Calif. — July 06, 2023 — Ultragenyx P |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 8, 2023 |
Exhibit 4.4 ULTRAGENYX PHARMACEUTICAL INC. 2023 INCENTIVE PLAN 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. 2. PURPOSE The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock-based and other incentive Awards. 3. ADM |
|
| June 8, 2023 |
Amended and Restated 2014 Employee Stock Purchase Plan Exhibit 4.5 ULTRAGENYX PHARMACEUTICAL INC. 2014 EMPLOYEE STOCK PURCHASE PLAN (as amended and restated effective as of June 7, 2023) Section 1. Defined Terms Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. Section 2. Purpose of Plan The Plan is intended to enable Eligible Employees of the Company and |
|
| June 8, 2023 |
First Amendment to Employment Inducement Plan Exhibit 4.7 FIRST AMENDMENT TO THE Ultragenyx Pharmaceutical Inc. Employment Inducement Plan WHEREAS, Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Company”) maintains the Ultragenyx Pharmaceutical Inc. Employment Inducement Plan (the “Plan”); and WHEREAS, pursuant to Section 9 of the Plan, the Compensation Committee may amend the Plan at any time and for any purpose as permitted by |
|
| June 8, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) ULTRAGENYX PHARMACEUTICAL INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 5, 2023 |
Exhibit 99.1 Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) Pediatric data show substantial induction of bone production in 1 week and a large increase in bone formation within 3 months of initiating monthly setrusumab treatment Phase 3 sites beginning to screen patients Conference call to discuss d |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 5, 2023 |
Form of Performance Stock Unit Agreement (2023) Exhibit 10.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS A PRIVATE OR CONFIDENTIAL. Name: [●] Target Number of Performance Stock Units subject to Award: [●] Date of Grant: [●] ULTRAGENYX PHARMACEUTICAL INC. 2014 INCENTIVE PLAN PERFORMANCE STOCK UNIT |
|
| May 5, 2023 |
Exhibit 10.3 May 1, 2023 Camille Bedrosian M.D. Re: Amendment No. 2 to Offer Letter Dear Camille: On behalf of Ultragenyx Pharmaceutical Inc. (the “Company”), I am pleased to present to you this Amendment No. 2 (this “Amendment”), which amends the Offer of Employment Letter Agreement with you dated January 15, 2018, as amended on September 13, 2022 (the “Offer Letter”) pursuant to the terms set fo |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| May 5, 2023 |
Exhibit 10.2 March 31, 2023 Eric Crombez, M.D. Dear Eric: Re: Amended and Restated Offer of Employment On behalf of Ultragenyx Pharmaceutical Inc. (the “Company”), I am pleased to offer you the position of Executive Vice President, Chief Medical Officer (“CMO”), on the following terms, commencing on May 1, 2023 (the “Effective Date”). The terms set forth below will be effective as of the Effective |
|
| May 4, 2023 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Media Jeff Blake [email protected] Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update First quarter 2023 total revenue of $100.5 million, Crysvita® revenue of $76.0 million and Dojolvi® revenue of $14.3 million Total revenue grew 26% and Crysvita revenue grew 28% versus the fir |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy |
|
| April 24, 2023 |
Notice of Annual Meeting of Stockholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 17, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) ULTRAGENYX PHARMACEUTICAL INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, |
|
| February 17, 2023 |
Lease, dated August 18, 2022, between Ultragenyx Pharmaceutical Inc. and Brickbottom I QOZB L.P. Exhibit 10.95 LEASE BY AND BETWEEN BRICKBOTTOM I QOZB LP LANDLORD AND ULTRAGENYX PHARMACEUTICAL INC. TENANT 100 Chestnut Street Somerville, Massachusetts NOTE: See Subsection 6.1.9 for provision regarding Tenant’s request for Landlord’s consent to Alterations and removal of the Alterations. TABLE OF CONTENTS Page Article 1 Reference Data 1 1.1 Introduction and Subjects Referred To 1 1.2 Exhibits 5 |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36276 Ultragenyx Pharmaceutical Inc |
|
| February 17, 2023 |
Subsidiaries of Ultragenyx Pharmaceutical Inc. Exhibit 21.1 Significant Subsidiaries of Ultragenyx Pharmaceutical Inc. Name of Subsidiary Jurisdiction of Incorporation Ultragenyx Holdco LLC Delaware Rare Delaware Inc. Delaware GeneTx Biotherapeutics LLC Delaware Ultragenyx UK Ltd United Kingdom Ultragenyx Europe GmbH Switzerland Ultragenyx Germany GmbH Germany Ultragenyx Brasil Farmacêutica Ltda Brazil Ultragenyx Argentina SRL Argentina Ultrag |
|
| February 17, 2023 |
As filed with the Securities and Exchange Commission on February 16, 2023 As filed with the Securities and Exchange Commission on February 16, 2023 Registration No. |
|
| February 17, 2023 |
Exhibit 10.92 THIRD AMENDMENT TO LEASE AGREEMENT THIS THIRD AMENDMENT TO LEASE AGREEMENT (this “Third Amendment”) is made as of July 27 , 2022, by and between ARE-SAN FRANCISCO NO. 17, LLC, a Delaware limited liability company (“Landlord”), and ULTRAGENYX PHARMACEUTICAL INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated as |
|
| February 17, 2023 |
Exhibit 10.25 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS A PRIVATE OR CONFIDENTIAL. Commercial Master Service Agreement Between Ultragenyx Pharmaceutical Inc. 60 Leveroni Court Novato, CA 94949 USA (Herein known as “UGX”) And BSP Pharmaceuticals S. |
|
| February 16, 2023 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Media Jeff Blake [email protected] Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update 2022 Total Collaboration and Product Revenue of $355.6 million, Crysvita® revenue of $279.4 million and Dojolvi® revenue of $55.6 million 2023 expected Total Revenue guidance be |
|
| February 16, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (C |
|
| February 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ultragenyx Pharmaceutical Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 90400B108 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pu |
|
| February 9, 2023 |
RARE / Ultragenyx Pharmaceutical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02110-ultragenyxpharmaceut.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Ultragenyx Pharmaceutical Inc. Title of Class of Securities: Common Stock CUSIP Number: 90400D108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ultragenyx Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90400D108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 10, 2023 |
RARE / Ultragenyx Pharmaceutical Inc / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 form774.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) ULTRAGENYX PHARMACEUTICAL, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 90400D108 (CUSIP Number) December 31, 2022 (Date of Ev |
|
| January 6, 2023 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Media Jeff Blake [email protected] Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones Preliminary 2022 Total Product Revenue of $352 million to $356 million, Crysvita? Revenue in Ultragenyx Territories1 of $257 million to $258 mill |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 06, 2023 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Co |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Ultragenyx Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90400D108 (CUSIP Number) November 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 ULTRAGENYX PHARMACEUTICAL INC. |
|
| November 3, 2022 |
Exhibit 10.7 September 13, 2022 Dennis Huang Re: Amendment No. 1 to Offer Letter Dear Dennis: On behalf of Ultragenyx Pharmaceutical Inc. (the ?Company?), I am pleased to present to you this Amendment No. 1 (this ?Amendment?), which amends the Offer of Employment Letter Agreement with you dated February 20, 2015 (the ?Offer Letter?) as follows: 1. The fourth paragraph under the heading ?Equity Gra |
|
| November 3, 2022 |
Exhibit 10.4 September 13, 2022 Mardi C. Dier Re: Amendment No. 2 to Offer Letter Dear Mardi: On behalf of Ultragenyx Pharmaceutical Inc. (the ?Company?), I am pleased to present to you this Amendment No. 2 (this ?Amendment?), which amends the Offer of Employment Letter Agreement with you dated August 28, 2020 and as amended by Amendment No. 1 dated October 9, 2020 (collectively, the ?Offer Letter |
|
| November 3, 2022 |
Exhibit 10.5 September 13, 2022 Thomas R. Kassberg Re: Amendment No. 2 to Offer Letter Dear Tom: On behalf of Ultragenyx Pharmaceutical Inc. (the ?Company?), I am pleased to present to you this Amendment No. 2 (this ?Amendment?), which amends the Offer of Employment Letter Agreement with you dated October 31, 2011 and as amended by Amendment No. 1 dated August 8, 2014 (collectively, the ?Offer Let |
|
| November 3, 2022 |
Exhibit 10.3 September 13, 2022 Camille Bedrosian M.D. Re: Amendment No. 1 to Offer Letter Dear Camille: On behalf of Ultragenyx Pharmaceutical Inc. (the ?Company?), I am pleased to present to you this Amendment No. 1 (this ?Amendment?), which amends the Offer of Employment Letter Agreement with you dated January 15, 2018 (the ?Offer Letter?) as follows: 1. The section with the heading ?Change of |
|
| November 3, 2022 |
Exhibit 10.9 September 13, 2022 John Pinion II Re: Amendment No. 1 to Offer Letter Dear John: On behalf of Ultragenyx Pharmaceutical Inc. (the ?Company?), I am pleased to present to you this Amendment No. 1 (this ?Amendment?), which amends the Offer of Employment Letter Agreement with you dated June 11, 2015 (the ?Offer Letter?) as follows: 1. The fourth paragraph under the heading ?Equity Grants? |
|
| November 3, 2022 |
Exhibit 10.6 September 13, 2022 Karah Parschauer Re: Amendment No. 1 to Offer Letter Dear Karah: On behalf of Ultragenyx Pharmaceutical Inc. (the ?Company?), I am pleased to present to you this Amendment No. 1 (this ?Amendment?), which amends the Offer of Employment Letter Agreement with you dated April 26, 2016 (the ?Offer Letter?) as follows: 1. The fourth paragraph under the heading ?Equity Gra |
|
| November 3, 2022 |
Exhibit 10.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT NO. 12 TO COLLABORATION AND LICENSE AGREEMENT This Amendment No. 12 to the Collaboration and License Agreement, (?Amendment?) is made and entered into by and between |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| November 3, 2022 |
Exhibit 10.2 AMENDMENT NO. 2 TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment No. 2 to Executive Employment Agreement (the ?Amendment?), dated September 13, 2022 (the ?Effective Date?), is between ULTRAGENYX PHARMACEUTICAL INC. (the ?Company?) and EMIL D. KAKKIS, M.D., PH.D. (the ?Executive?). Capitalized terms used but not defined herein have the meanings given to them in the Agreement (as define |
|
| November 3, 2022 |
Exhibit 10.8 September 13, 2022 Erik Harris Re: Amendment No. 3 to Offer Letter Dear Erik: On behalf of Ultragenyx Pharmaceutical Inc. (the ?Company?), I am pleased to present to you this Amendment No. 3 (this ?Amendment?), which amends your original offer of employment dated May 16, 2017 as amended by Addendum No. 1 dated August 3, 2015 and Addendum No. 2 dated June 19, 2019 (collectively, the ?O |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2022 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (C |
|
| November 2, 2022 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Media Jeff Blake [email protected] Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update Third quarter 2022 total revenue of $90.7 million and Crysvita? revenue in Ultragenyx territories1 of $64.5 million Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 mi |
|
| October 28, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of I |
|
| September 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 09, 2022 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) ( |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| July 29, 2022 |
Exhibit 10.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Royalty Purchase Agreement By and Between Rare Delaware Inc. Ultragenyx Pharmaceutical Inc. and OCM LS23 Holdings LP Dated as of July 14, 2022 -i- Table of Contents Page Artic |
|
| July 29, 2022 |
Exhibit 10.2 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED UNIT PURCHASE AGREEMENT by and among ULTRAGENYX PHARMACEUTICAL INC., GENETX BIOTHERAPEUTICS LLC, THE UNITHOLDERS LISTED ON SCHEDULE A and Deborah A. Guagliardo, as the Represe |
|
| July 28, 2022 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Media Jeff Blake [email protected] Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update Second quarter 2022 total revenue of $89.3 million and Crysvita? revenue in Ultragenyx territories1 of $64.0 million Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 |
|
| July 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 18, 2022 |
Exhibit 99.1 Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1/2 Study Doses up to 10 mg show good tolerability and meaningful clinical activity in multiple domains U.K. and Canadian health authorities approved escalation to higher doses Ultragenyx exercises option to acquire GeneTx for $75 million upfront payment Conference |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2022 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 14, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2022 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 14, 2022 |
Exhibit 99.1 Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets Strengthens balance sheet with non-dilutive capital at an attractive cost Competitive process results in the sale of 30% of the Ultragenyx royalty interest, subject to a 1.45x cap Proceeds to fund planned clinical and commercial activities NOVATO |
|
| June 27, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 17, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 17, 2022 |
Exhibit 99.1 Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA Interim data featured in encore oral presentation at American Society of Gene & Cell Therapy (ASGCT) today NOVATO, Calif., NEW YORK, NY and CLEVELAND, OH ? MAY |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| May 6, 2022 |
Form of Performance Stock Unit Agreement (2022) Exhibit 10.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Name: [?] Target Number of Performance Stock Units subject to Award: [?] Date of Grant: [?] ULTRAGENYX PHARMACEUTICAL INC. 2014 INCENTIVE PLAN PERFORMANCE STOCK UNIT AGREEMENT |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2022 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 5, 2022 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Media Jeff Blake [email protected] Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update First quarter 2022 total revenue of $79.9 million and Crysvita? revenue in Ultragenyx territories1 of $54.6 million Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 mi |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2022 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 15, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) ULTRAGENYX PHARMACEUTICAL INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, |
|
| February 15, 2022 |
As filed with the Securities and Exchange Commission on February 15, 2022 As filed with the Securities and Exchange Commission on February 15, 2022 Registration No. |
|
| February 15, 2022 |
Exhibit 10.20 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED SeCOND AMENDMENT TO OPTION and License Agreement This SECOND AMENDMENT TO OPTION AND LICENSE AGREEMENT (?Second Amendment?) is entered into as of December 17, 2021 (?Second A |
|
| February 15, 2022 |
Exhibit 10.13 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT NO. 11 TO COLLABORATION AND LICENSE AGREEMENT This Amendment No. 11 to the Collaboration and License Agreement, (?Amendment?) is made and entered into by and betwee |
|
| February 15, 2022 |
Subsidiaries of Ultragenyx Pharmaceutical Inc. Exhibit 21.1 Significant Subsidiaries of Ultragenyx Pharmaceutical Inc. Name of Subsidiary Jurisdiction of Incorporation Ultragenyx Holdco LLC Delaware Ultragenyx UK Ltd United Kingdom Ultragenyx Europe GmbH Switzerland Ultragenyx Germany GmbH Germany Ultragenyx Brasil Farmac?utica Ltda Brazil Ultragenyx Argentina SRL Argentina Ultragenyx Netherlands B.V. Netherlands Ultragenyx France SAS France U |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36276 Ultragenyx Pharmaceutical Inc |
|
| February 14, 2022 |
RARE / Ultragenyx Pharmaceutical Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) ULTRAGENYX PHARMACEUTICAL, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 90400D108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Fili |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Ultragenyx Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90400D108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2022 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (C |
|
| February 10, 2022 |
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa [email protected] Media Jeff Blake [email protected] Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update 2021 total revenue of $351.4 million and 2021 Crysvita? revenue in Ultragenyx territories1 of $192.6 million 2022 Crysvita revenue in Ultragenyx territories guidance of $250 mil |
|
| February 10, 2022 |
RARE / Ultragenyx Pharmaceutical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Ultragenyx Pharmaceutical Inc. Title of Class of Securities: Common Stock CUSIP Number: 90400D108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 10, 2022 |
Exhibit 99.1 ULTRAGENYX REPORTS PRELIMINARY 2021 REVENUE AND 2022 REVENUE GUIDANCE FOR CRYSVITA? IN ULTRAGENYX TERRITORIES* AND DOJOLVI? GLOBALLY; PROVIDES PIPELINE UPDATES AND 2022 MILESTONES Preliminary 2021 Crysvita revenue in Ultragenyx territories of $191 million to $193 million and Dojolvi revenue of $38 million to $40 million 2022 Crysvita revenue in Ultragenyx territories expected in the r |
|
| January 7, 2022 |
Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza EX-99.1 2 rare-ex991.htm EX-99.1 Exhibit 99.1 Press Release Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States Evkeeza is a first-in-class medicine approved by the U.S. Food and Drug Administration (FDA) and European Commission (EC) to treat an ultra-rare inherited form of high cholesterol TARRYTOWN, N.Y. and NOVATO, C.A., January 7, 2022 – Regene |
|
| January 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 07, 2022 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Co |
|
| November 3, 2021 |
Amendment No. 1 to the Ultragenyx Pharmaceutical Inc. Deferred Compensation Plan Exhibit 10.1 ULTRAGENYX PHARMACEUTICAL INC. DEFERRED COMPENSATION PLAN AMENDMENT NO. 1 October 1, 2021 Section 9.2 of the Ultragenyx Pharmaceutical Inc. Deferred Compensation Plan (the ?Plan?) authorizes Ultragenyx Pharmaceutical Inc. (the ?Company?) to amend the Plan at any time. Accordingly, the Plan is amended to provide ? for a one-time transition election during the 2021 annual enrollment for |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| November 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2021 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (C |
|
| November 2, 2021 |
Exhibit 99.1 Contact Ultragenyx Pharmaceutical Inc. Investors Joshua Higa (415) 475-6370 [email protected] Media Carolyn Wang 415-225-5050 [email protected] Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update Third quarter 2021 total revenue of $81.6 million including Crysvita1 revenue to Ultragenyx of $50.3 million 2021 Crysvita revenue in Ultragenyx territories1 now e |
|
| October 26, 2021 |
ARCT / Arcturus Therapeutics Ltd. / Ultragenyx Pharmaceutical Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) ARCTURUS THERAPEUTICS HOLDINGS INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03969T109 (CUSIP Number) Karah Parschauer Executive Vice President, General Counsel Ultragenyx Pharmaceutical Inc. 60 Leveroni Cou |
|
| October 8, 2021 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8 )* Ultragenyx Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90400D108 (CUSIP Number) September 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| October 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 07, 2021 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Co |
|
| October 7, 2021 |
Exhibit 99.1 GeneTx and Ultragenyx Announce First Patient Dosed in Canada in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome SARASOTA, Fla., and NOVATO, Calif. ? October 7, 2021 ? GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102, an investigational treatment for Angelman syndrome, today announced |
|
| September 27, 2021 |
Exhibit 99.1 GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold on Phase 1/2 Clinical Study of GTX-102 for the Treatment of Angelman Syndrome in the U.S. SARASOTA, Fla. and NOVATO, Calif ? September 27, 2021 ? GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102, an investigational treatment for Angelman syndrome, |
|
| September 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) ( |
|
| August 12, 2021 |
ARCT / Arcturus Therapeutics Ltd. / Ultragenyx Pharmaceutical Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) ARCTURUS THERAPEUTICS HOLDINGS INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03969T109 (CUSIP Number) Karah Parschauer Executive Vice President, General Counsel Ultragenyx Pharmaceutical Inc. 60 Leveroni Cou |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| August 3, 2021 |
Form of Non-Statutory Stock Option Agreement (Annual Grant for Directors) Exhibit 10.2 Name: Number of Shares of Stock subject to Stock Option: Price Per Share: Date of Grant: Vesting Start Date: Ultragenyx Pharmaceutical Inc. 2014 Incentive Plan Non-statutory Stock Option Agreement (Directors) This agreement (this ?Agreement?) evidences a stock option granted by Ultragenyx Pharmaceutical Inc. (the ?Company?) to the undersigned (the ?Optionee?) pursuant to and subject t |
|
| August 3, 2021 |
Form of Restricted Stock Unit Agreement (Annual Grant for Directors) Exhibit 10.3 Name: Number of Restricted Stock Units subject to Award: Date of Grant: Ultragenyx Pharmaceutical Inc. 2014 Incentive Plan Restricted Stock Unit Agreement (Directors) This agreement (this ?Agreement?) evidences an award (the ?Award?) of restricted stock units (the ?Restricted Stock Units?) granted by Ultragenyx Pharmaceutical Inc. (the ?Company?) to the undersigned (the ?Grantee?) pur |
|
| August 3, 2021 |
Form of Non-Statutory Stock Option Agreement (Grant for New Directors) Exhibit 10.4 Name: Number of Shares of Stock subject to Stock Option: Price Per Share: Date of Grant: Vesting Start Date: Ultragenyx Pharmaceutical Inc. 2014 Incentive Plan Non-statutory Stock Option Agreement (Directors) This agreement (this ?Agreement?) evidences a stock option granted by Ultragenyx Pharmaceutical Inc. (the ?Company?) to the undersigned (the ?Optionee?) pursuant to and subject t |
|
| August 3, 2021 |
Form of Restricted Stock Unit Agreement (Grant for New Directors) Exhibit 10.5 Name: Number of Restricted Stock Units subject to Award: Date of Grant: Ultragenyx Pharmaceutical Inc. 2014 Incentive Plan Restricted Stock Unit Agreement (Directors) This agreement (this ?Agreement?) evidences an award (the ?Award?) of restricted stock units (the ?Restricted Stock Units?) granted by Ultragenyx Pharmaceutical Inc. (the ?Company?) to the undersigned (the ?Grantee?) pur |
|
| August 3, 2021 |
Ultragenyx Pharmaceutical Inc. Deferred Compensation Plan Exhibit 10.1 Ultragenyx Pharmaceutical Inc. Deferred Compensation Plan Effective Date June 10, 2021 Content Copyright ?2018 Newport Group, Inc. All Rights Reserved. Ultragenyx Pharmaceutical Inc. Deferred Compensation Plan Article I Establishment and Purpose1 Article II Definitions1 Article III Eligibility and Participation7 Article IV Deferrals7 Article V Company Contributions11 Article VI Paymen |
|
| August 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 02, 2021 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 2, 2021 |
Exhibit 99.1 Contact Ultragenyx Pharmaceutical Inc. Investors Joshua Higa (415) 475-6370 Media Carolyn Wang 415-225-5050 Ultragenyx Reports Second Quarter 2021 Financial Results and Corporate Update Second quarter 2021 total revenue of $87.0 million including Crysvita1 revenue to Ultragenyx of $44.7 million 2021 Crysvita revenue in Ultragenyx territories1 guidance of $180 million to $190 million r |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 25, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 10, 2021 |
Exhibit 99.1 GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome Patient enrollment to begin in early second half of 2021 in U.K. and Canada GeneTx to submit revised protocol to U.S. Food and Drug Administration seeking study resumption in U.S. following May meeting SARASOTA, Fla. and NOVATO, Calif ? June 10, |
|
| May 19, 2021 |
EX-99.1 2 rare-20210519-ex991.htm EX-99.1 Exhibit 99.1 GeneTx and Ultragenyx Receive Clearance from Health Canada to Begin Clinical Study of GTX-102 in Canada for the Treatment of Angelman Syndrome SARASOTA, Fla. and NOVATO, Calif — May 19, 2021 — GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-1 |
|
| May 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 14, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 14, 2021 |
EX-99.1 2 rare-20210514-ex991.htm EX-99.1 Exhibit 99.1 Ultragenyx Announces Positive Multi-Year Durability Data from Ongoing Phase 1/2 Gene Therapy Studies and Data on HeLa 3.0 Manufacturing Platform at American Society of Gene & Cell Therapy 2021 Annual Meeting Durable and Clinically Meaningful Responses Maintained at More than 2.5 and 3 Years Post-Treatment in Phase 1/2 Studies of DTX401 for GSD |
|
| May 7, 2021 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM May 7, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s comm |
|
| May 7, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-253008 PROSPECTUS SUPPLEMENT (To Prospectus dated February 12, 2021) $350,000,000 Common Stock We have entered into an Open Market Sale AgreementSM (the ?Sale Agreement?) with Jefferies LLC (?Jefferies?), relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In |
|
| May 7, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2021 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| May 5, 2021 |
Form of Performance Stock Unit Agreement (2021) Exhibit 10.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Name [?] Target Number of Performance Stock Units subject to Award: [?] Date of Grant: [?] ULTRAGENYX PHARMACEUTICAL INC. 2014 INCENTIVE PLAN PERFORMANCE STOCK UNIT AGREEMENT |
|
| May 4, 2021 |
Exhibit 99.1 Contact Ultragenyx Pharmaceutical Inc. Investors & Media Joshua Higa (415) 475-6370 Ultragenyx Reports First Quarter 2021 Financial Results and Corporate Update First quarter 2021 total revenue of $99.4 million and Crysvita1 revenue to Ultragenyx of $42.1 million 2021 Crysvita revenue in Ultragenyx territories1 guidance of $180 million to $190 million reaffirmed Strong Dojolvi launch |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2021 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 29, 2021 |
DEF 14A 1 lrare2021def14a.htm ULTRAGENYX PHARMACEUTICAL INC. - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant |
|
| April 29, 2021 |
- ULTRAGENYX PHARMACEUTICAL INC. - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement CONFIDENTIAL, F |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2021 Ultragenyx Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36276 27-2546083 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 )* Ultragenyx Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90400D108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Ultragenyx Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90400D108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Ultragenyx Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90400D108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 12, 2021 |
As filed with the Securities and Exchange Commission on February 11, 2021 Registration No. |
|
| February 12, 2021 |
As filed with the Securities and Exchange Commission on February 11, 2021 Registration No. |
|
| February 12, 2021 |
Exhibit 4.2 ULTRAGENYX PHARMACEUTICAL INC. Debt Securities Indenture Dated as of , 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c) 12.02 (d) 7. |
|
| February 12, 2021 |
EX-10.83 12 rare-ex1083597.htm EX-10.83 Exhibit 10.83 SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (this “Second Amendment”) is made as of October 21, 2020, by and between ARE-SAN FRANCISCO NO. 17, LLC, a Delaware limited liability company (“Landlord”), and ULTRAGENYX PHARMACEUTICAL INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now par |
